Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
NEW YORK, Nov. 02, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment community on Thursday, November 9, 2017, at 8:00 a.m. Eastern Time.
The conference call will feature remarks by Dr. Lan Huang, Ph.D., Chairman and CEO, and Richard Brand, CFO. The dial-in numbers for the conference call are +1.855.327.6838 (U.S. Toll Free) or +1.604.235.2082 (International). Please ask the operator to join you into the BeyondSpring Call.
A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the call will be available through November 23, 2017, at +1.844.512.2921 (U.S. Toll Free) or +1.412.317.6671 (International). Participants must use the following code to access the replay of the call: 10003794. Also, a replay of the webcast will remain available on http://ir.beyondspringpharma.com for 30 days following the call.
The Company also plans to issue an operational update press release on Thursday, November 9, 2017 before the U.S. markets open, which will include its financial results for the quarter ended September 30, 2017.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical program in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Investor Relations:
Steve Silver / Jeffrey Goldberger
KCSA Strategic Communications
P: +1-212-682-6300
[email protected] / [email protected]
Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
[email protected] / [email protected]
